Abstract
Fourteen patients with chronic pain of malignant origin were treated with escalating doses of THIP intramuscularly 5-30 mg in an open phase 1 study. Analgesic activity was demonstrated in 60% of the patients at the level of 20 mg THIP and a dose response relation was present. Side effects, sedation, dizziness, euphoria, nausea, and blurred vision were present in up to 80% of the patients and were dose limiting. The maximum serum concentration was reached within 1 h after dosing in 87% of all administrations. Mean t1/2 was 1.52 +/- 0.63 h and the clearance was 0.49 +/- 0.181 min. Significant correlations were demonstrated between serum concentration, dose of THIP, analgesic effect and side effects. It is concluded that THIP cannot be used for the treatment of chronic cancer pain, not because of insufficient analgesic effect but because of unacceptable side effects.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Christensen A. V., Larsen J. J. Antinociceptive and anticonvulsive effect of THIP, a pure GABA agonist. Pol J Pharmacol Pharm. 1982;34(1-3):127–134. [PubMed] [Google Scholar]
- Christensen A. V., Svendsen O., Krogsgaard-Larsen P. Pharmacodynamic effects and possible therapeutic uses of THIP, a specific GABA-agonist. Pharm Weekbl Sci. 1982 Oct 22;4(5):145–153. doi: 10.1007/BF01959034. [DOI] [PubMed] [Google Scholar]
- Hill R. C., Maurer R., Buescher H. H., Roemer D. Analgesic properties of the GABA-mimetic THIP. Eur J Pharmacol. 1981 Jan 16;69(2):221–224. doi: 10.1016/0014-2999(81)90419-2. [DOI] [PubMed] [Google Scholar]
- Kjaer M., Henriksen H., Knudsen J. A comparative study of intramuscular buprenorphine and morphine in the treatment of chronic pain of malignant origin. Br J Clin Pharmacol. 1982 Apr;13(4):487–492. doi: 10.1111/j.1365-2125.1982.tb01409.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Korsgaard S., Casey D. E., Gerlach J., Hetmar O., Kaldan B., Mikkelsen L. B. The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist. Arch Gen Psychiatry. 1982 Sep;39(9):1017–1021. doi: 10.1001/archpsyc.1982.04290090021005. [DOI] [PubMed] [Google Scholar]
- Lindeburg T., Følsgård S., Sillesen H., Jacobsen E., Kehlet H. Analgesic, respiratory and endocrine responses in normal man to THIP, a GABA-agonist. Acta Anaesthesiol Scand. 1983 Feb;27(1):10–12. doi: 10.1111/j.1399-6576.1983.tb01896.x. [DOI] [PubMed] [Google Scholar]
- Madsen S. M. Quantitative determination of the gamma-aminobutyric acid agonist, 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol, in serum by high-performance liquid chromatography. J Chromatogr. 1983 May 13;274:209–218. doi: 10.1016/s0378-4347(00)84424-2. [DOI] [PubMed] [Google Scholar]
- Schultz B., Aaes-Jørgensen T., Bøgesø K. P., Jørgensen A. Preliminary studies on the absorption, distribution, metabolism, and excretion of THIP in animal and man using 14C-labelled compound. Acta Pharmacol Toxicol (Copenh) 1981 Aug;49(2):116–124. doi: 10.1111/j.1600-0773.1981.tb00879.x. [DOI] [PubMed] [Google Scholar]
- Snyder S. H. The opiate receptor and morphine-like peptides in the brain. Am J Psychiatry. 1978 Jun;135(6):645–652. doi: 10.1176/ajp.135.6.645. [DOI] [PubMed] [Google Scholar]